Conventional models of ligand±receptor regulation predict that agonists enhance the tone of signals generated by the receptor in the absence of ligand. Contrary to this paradigm, stimulation of the type 2 (AT 2 ) receptor by angiotensin II (Ang II) is not required for induction of apoptosis but the level of receptor protein expression is critical. We compared Ang II-dependent and -independent AT 2 receptor signals involved in regulating apoptosis of cultured ®bro-blasts, epithelial cells and vascular smooth muscle cells. We found that induction of apoptosisÐblocked by pharmacological inhibition of p38 mitogen-activated protein kinase and caspase 3Ðis a constitutive function of the AT 2 receptor. Biochemical and genetic studies suggest that the level of AT 2 receptor expression is critical for physiological ontogenesis and its expression is restricted postnatally, coinciding with cessation of developmental apoptosis. Re-expression of the AT 2 receptor in remodeling tissues in the adult is linked to control of tissue growth and regeneration. Therefore, we propose that overexpression of the AT 2 receptor itself is a signal for apoptosis that does not require the renin±angiotensin system hormone Ang II.
Introduction
Hormonal regulation of in vivo functions of the type 2 receptor (AT 2 ) for the octapeptide angiotensin II [Ang II (Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 -Phe 8 -COO ± )] is an enigma. Ang II is an important mediator of the renin± angiotensin system's functions. Almost all of the classical physiological effects attributed to Ang II regulation are mediated by the Ang II type 1 (AT 1 ) receptor, leaving an unexplained role for the AT 2 receptor in the renin± angiotensin system. Ang II is widely regarded as the physiological ligand for the AT 2 receptor, although Ang II binding does not elicit the usual second-messenger responses or desensitization and down-regulation of the AT 2 receptor, the biochemical responses considered hallmarks of ligand regulation of receptor functions (Bottari et al., 1991; Brechler et al., 1993; Hein et al., 1995 Hein et al., , 1997 Ichiki et al., 1995; Matsubara, 1998; Horiuchi et al., 1999) . Expression of the AT 2 receptor is developmentally regulated; genetic defects in it are linked to attenuated apoptosis of mesenchymal cells, contributing to aberrant ontogenesis of the kidney and urinary tract (Nishimura et al., 1999) . Apoptosis in cultured pheochromocytoma and ®broblast cell lines is accompanied by overexpression of the AT 2 receptor (Yamada et al., 1996; Matsubara, 1998; Nishimura et al., 1999) . AT 2 receptor gene knockout leads to defective navigational control in mice (Hein et al., 1995; Ichiki et al., 1995) . Transgenic cardiac overexpression leads to malfunctioning pacemaker cells and abnormal blood pressure regulation (Masaki et al., 1998) . Besides contributing to apoptosis through signals, the AT 2 receptor is reported to regulate activities of the mitogen-activated protein kinase (MAPK), inward recti®er potassium channel, T-type calcium channel, protein tyrosine phosphatase SHP-1 and protein phosphatase 2B (for a review see Matsubara, 1998) .
The AT 2 receptor is a seven transmembrane (7TM) helical receptor that binds subtype selective ligand PD123319 and CGP42112 (Brechler et al., 1993) . It is an atypical receptor with regard to agonist recognition, GTP analogue-dependent agonist af®nity modulation, Gprotein coupling, and the ability to activate secondmessenger pathways (Bottari et al., 1991; Pucell et al., 1991; Brechler et al., 1993; Nakajima et al., 1995; Miura and Karnik, 1999) . Although the AT 2 receptor contains consensus sites for phosphorylation, it is not phosphorylated in response to Ang II and does not internalize (Hein et al., 1997) . Abundant expression of the AT 2 receptor in fetal tissues is essential for physiological ontogenesis. Its expression in adults is limited to few tissues, but reexpressed~5-to 25-fold over basal during remodeling of tissues where the AT 2 receptor is thought to play a role in the apoptosis of smooth muscle cells, ®broblasts and endothelial cells (Bottari et al., 1991; Pucell et al., 1991; Stoll et al., 1995; Dimmeler et al., 1997; Matsubara, 1998; Horiuchi et al., 1999) . Thus, the importance of AT 2 receptor functions is beginning to be documented, but there is still no explanation of how Ang II regulates the receptor's functions.
In an earlier study (Miura and Karnik, 1999) we elucidated that the chemical groups on Ang II essential for high af®nity binding to the AT 2 receptor each contributed only a small proportion (<10%) of the overall binding energy. It is generally believed that the high af®nity of hormones is a consequence of their selective binding to receptors that are already active, so that the hormone shifts the equilibrium in favor of active receptors. Alternatively, hormones could bind to inactive receptors and facilitate isomerization to the active state and stabilize the active receptor (Gether and Kobilka, 1998; Karnik, 2000) . In either mechanism, agonist analogs, differing in the ability to in¯uence activation, also display large differences in af®nity. The lack of af®nity discrimination of Ang II analogs (Miura and Karnik, 1999) suggested to us that either the native AT 2 receptor is already in an active state or Ang II is not a classical agonist for the AT 2 receptor. The current study explores the speci®city of the Ang II±AT 2 receptor complex in the regulation of signals that contribute to apoptosis. Our results suggest that the AT 2 receptor, without Ang II stimulation, generates signals that are critical for the cell death program. Also, consistent with Ang II-independent regulation, the AT 2 receptor-induced apoptosis of R3T3 ®broblasts, Chinese hamster ovary (CHO) epithelial cells and the A7r5 vascular smooth muscle cells (VSMCs) is not further enhanced by Ang II.
Results and discussion
Apoptosis in R3T3 ®broblasts may not require Ang II Whether Ang II is essential in vivo for the AT 2 receptor to mediate apoptosis during embryonic development or physiological and pathological remodeling is unclear. The R3T3 ®broblast cell line has been used as a model for study since apoptosis in these cells resembles the in vivo situation described in ovarian granulosa cells and other remodeling tissues (Pucell et al., 1991; Stoll et al., 1995; Yamada et al., 1996; Matsubara, 1998; Speth et al., 1999) . AT 2 receptor overexpression precedes apoptosis in conuent R3T3 cells, which express low levels of AT 1 and AT 2 receptors (2 6 0.4 versus 9 6 0.3 fmol/mg protein) when grown in serum. Serum starvation leads to añ 10-fold increase in AT 2 receptor density in the con¯uent state (see Figure 1) . However, in non-con¯uent R3T3 cells, serum depletion itself was suf®cient to induce apoptosis, which was not accompanied by an increase in AT 2 receptor density. However, addition of Ang II was not required for induction of apoptosis and the apoptosis could not be blocked by the AT 2 receptor-selective antagonist PD123319 (not shown). Thus, the up-regulation of AT 2 receptor gene expression might be a signal for apoptosis in vivo. These results are qualitatively similar to those reported in several cultured cell models that lead to the conclusion that Ang II is required to induce apoptosis via the AT 2 receptor. Since our ®nding differs signi®cantly with regard to the speci®city of apoptosis induction by the Ang II±AT 2 receptor complex, we conclude that it is dif®cult to separate the critical effects of culture conditions and AT 2 receptor overexpression on induction of apoptosis. Hence, the AT 2 receptor-expressing native cell lines are not a suitable model to conclude the requirement of an Ang II±AT 2 receptor complex for apoptosis and are even less appropriate to conclude a role for induced overexpression of AT 2 receptor protein. Cell models where levels of AT 2 receptor expression can be controlled are better suited for these studies.
AT 2 receptor expression induces apoptosis in CHO cells and VSMCs To link de novo expression of AT 2 receptor to apoptosis, we used the CHO and A7r5 cells as surrogate models (Figure 2 ). CHO cells are an established epithelial lineage of non-transformed cells that are capable of growing under low-serum conditions with appropriate supplements (Kao and Puck, 1968) . A7r5 is an established cell line that retains several smooth muscle characteristics (Kimes and Brandt, 1976) . VSMCs, a key component of the blood vessels, is a relevant cell model because it is subjected to apoptotic and mitogenic stimulation, respectively, by AT 2 and AT 1 receptors in vivo (Kimes and Brandt, 1976; Stouffer and Owens, 1992; Duff et al., 1995; Horiuchi et al., 1999) . Expression of the endogenous AT 2 receptor is undetectable by 125 I-[Sar 1 -Ile 8 ]Ang II binding and RT± PCR using AT 2 receptor mRNA-speci®c primers, under conditions of both serum-stimulated growth and serum deprivation in both these cell lines. The endogenous AT 1 receptor (<18 6 6 fmol/mg protein) does not elicit any signi®cant inositol phosphate production and MAPK phosphorylation. However, transfection of AT 1 receptor cDNA elicited both these responses, indicating that the signal transduction components are present in both cell lines. RT±PCR analysis indicated that these cells do not express angiotensinogen, a key source of intracellular Ang II production and paracrine/autocrine regulation (data not shown). Therefore, by introducing the AT 2 receptor in these cells, its effects on apoptosis can be studied without the hypertrophic or mitogenic signaling from the AT 1 receptor and/or autocrine in¯uence of Ang II.
Exogenous overexpression of the AT 2 receptor induced apoptosis in both CHO and A7r5 cells. Nuclear DNA condensation and fragmentation began~24 h (time at which growth arrest is established) after shifting to the low-serum growth condition and was complete after 72 h (Figure 2 ). Speci®cally in the enhanced yellow¯uorescent protein (EYFP)-positive cells transfected with pAT 2 R-EYFP, morphological features associated with the apoptotic cells, such as irregular shaped nuclei in conjunction with chromatin condensation, appeared ( Figure 2C and G). These cells also exhibited membrane blebbing, cytoplasmic shrinkage and inhibition of protein synthesis (data not shown). In contrast, 4¢,6-diamidino-2-phenylindole (DAPI) staining of the pEYFP-transfected control cell nuclei showed sharp round edges and diffuse chromatin (Figure 2A and E). These cells did not exhibit apoptotic features, indicating that the observed apoptosis is speci®c for the AT 2 receptor and is not an artifact of transfection, serum deprivation or EYFP expression.
The APO-BRDUÔ chromatin DNA fragmentation method was used to quantitate the percentage of cells in apoptosis, employing¯uorescence activated cell sorter (FACS) analysis (Figures 3 and 4 ; see Materials and methods for details). Fluorescein-labeled DNA break points (green) shown in Figure 3A illustrate nuclei in To evaluate the ability of the AT 2 receptor protein to induce apoptosis directly, we expressed different levels of the receptor in A7r5 cells and measured the percentage of cells in apoptosis by FACS analysis ( Figure 4A ). Transfecting variable mixtures of the expression vector with and without the AT 2 receptor cDNA insert (see Materials and methods for details) led to variable levels of expression of the AT 2 receptor that were directly correlated with the percentage of cells undergoing apoptosis (r = 0.97; y = 4.8 + 0.15x; n = 19). An average of 50% cells are in apoptosis when the AT 2 receptor level is 300 fmol/mg protein ( Figure 4B ). The expression level of AT 2 receptor in normal adult tissues is~10±20 fmol/mg protein. The expression level is~260 fmol/mg protein in 18-day fetal tissue (Viswanathan et al., 1991) ,~453 fmol/ mg protein in the atretic ovarian follicular membrane (Speth et al., 1999) and~345 fmol/mg protein in con¯uent mesangial cells (Goto et al., 1997) . In most model systems a signi®cant increase in AT 2 receptor mRNA, but not the exact receptor numbers, is reported. Therefore, the expression level of~300 fmol/mg protein was used for pharmacological studies (see later).
A speci®c conformation of the AT 2 receptor is necessary for induction of apoptosis Overexpression of AT 2 receptors on the cell surface could abrogate cell±matrix interaction or the cell's access to essential sustenance for growth. To determine whether the Novel signaling by 7TM receptor overexpression of the protein or the speci®c function of the native receptor is responsible for the apoptosis induced by the AT 2 receptor, we transfected the N127G mutant ( Figure 3B ). This mutation decreases the af®nity of the antagonist PD123319 80-fold. The af®nity of the agonist [Sar 1 ]Ang II and various agonist analogs is also decreased 2-to 20-fold, suggesting that the conformation of the mutant receptor is different from that of the wild-type (WT) AT 2 receptor. The N127G mutant AT 2 receptor was expressed on the plasma membrane in the A7r5 and CHO cells, and the expression level of the mutant was comparable to that of the WT AT 2 receptor (B max of WT versus N127G is 605 6 15 versus 540 6 20 fmol/mg protein in A7r5 cells and 1030 6 40 versus 1250 6 50 fmol/mg protein in CHO cells). The maximum apoptosis induced by the N127G mutant was~10% of that induced by the WT AT 2 receptor in both cell lines. [Sar 1 ]Ang II at 1±10 mM (>100-fold over K d ) did not stimulate apoptosis in both A7r5 and CHO cells transfected with the N127G mutant, indicating that decreased agonist af®nity is not the cause of the defect in this mutant. Thus, cell surface expression of the AT 2 receptors is not suf®cient, rather the observations suggest a speci®c conformation attained by the WT protein to induce apoptosis in a concentration-dependent manner. Apoptosis in the CHO cells correlated with the level of expression of the WT AT 2 receptor. Expression of the N127G mutant did not induce apoptosis in CHO cells ( Figure 3B ). Thus, no unique characteristic feature of smooth muscle cells seems to be critical for AT 2 receptor to induce apoptosis.
AT 2 receptor-induced apoptosis is mediated by p38 MAPK and caspase-3 Mechanisms for the recruitment of distinct members of the MAPK superfamily and caspase family do exist in the AT 2 receptor. Pharmacological inhibition of p38 MAPK and caspase-3 blocked apoptosis induced by two different levels of AT 2 receptor expression in A7r5 cells ( Figures 5±  7) . The p38 MAPK-speci®c inhibitor SB203580 blocked AT 2 receptor-induced apoptosis by~80%. The SB203580 inhibitor alone had no signi®cant effect on A7r5 cells. The maximal inhibitory effect of SB203580 (10 mM) occurred when the inhibitor was present during serum starvation; this inhibitor was not effective when added 24 h after serum starvation, suggesting a small time window for its action. Immunoblot analysis indicated that a protein of 44 kDa that cross-reacted with p38 MAPK-speci®c antiserum is present in A7r5 cells ( Figure 6A ). VSMCs have also been shown to contain p38 MAPK (Kusuhara et al., 1998) . In AT 2 receptor-transfected cells, basal levels of both p38 MAPK and phospho-p38 MAPK were elevated. In contrast, cells transfected with empty vector or the N127G mutant contained lower levels of mostly non-phosphorylated p38 MAPK ( Figure 6A ). Treatment with [Sar 1 ]Ang II did not further increase phospho-p38 MAPK levels but treatment with SB203580 decreased levels in these cells. PD123319 treatment had no effect. None of the treatments affected p38 MAPK levels ( Figure 6B ). These results suggest a signi®cant functional role for p38 MAPK in AT 2 receptor-mediated apoptotic signaling.
To characterize the roles of p42/44 MAPK in AT 2 receptor-induced apoptosis, we measured the effect of PD98059, a speci®c inhibitor of MEK, on the AT 2 receptor-stimulated apoptosis ( Figure 5 ). PD98059 at 30 mM, a concentration that blocked accumulation of phospho-p42/44 MAPK, alone did not induce apoptosis, nor did it potentiate an apoptotic response to AT 2 receptor expression (not shown). MEK activates p42/44 MAPK by phosphorylation and the AT 2 receptor-coupled MAPKphosphatase 1 dephosphorylates p42/44 MAPK (Yamada et al., 1996) . Down-regulation of p42/p44 MAPK activity in VSMCs, neuroblastoma cells, cultured primary neurons and rat ®broblasts has been suggested to contribute to the anti-growth effect associated with the AT 2 receptor (Duff et al., 1995; Nakajima et al., 1995; Huang et al., 1996; Yamada et al., 1996) . However, this regulatory loop does not seem to be critical in the apoptotic pathway, but may have a role in exerting an anti-growth effect. We did not investigate the activation of the c-jun-kinase, because an increase in its activity is slower and speci®c inhibitors do not yet exist. Furthermore, nearly complete blockade of apoptosis by SB203580 is indicative of an exclusive role of p38 MAPK in AT 2 receptor-induced apoptosis.
We examined activation of caspases since the activation of class II caspases, a process essential for the execution of catastrophic proteolysis of regulatory proteins in a cell destined to die, is considered a hallmark of programmed cell death (Ashkenazi and Dixit, 1998) . The caspase-3 inhibitor Ac-DEVD-cmk (1 mM) inhibited~30% of the AT 2 receptor-induced apoptosis ( Figure 5 ). The partial blockade might be because this class of inhibitors are not very potent. The measured caspase-3-like activity in cellfree extracts prepared from WT AT 2 receptor-transfected cells was signi®cantly higher than that in pcDNA3-transfected (mock) and N127G mutant-transfected cells (Figure 7) . The increase in caspase-3-like activity in the WT AT 2 receptor-transfected cells was not suppressed by the antagonist PD123319. The observations that N127G mutant receptor does not induce apoptosis or activate caspase-3-like activity and that the WT receptor activates caspase-3-like activity suggest that this activity is critical for induction of apoptosis. The involvement of other caspases in the process can not be ruled out. Thus, the activation and involvement of the caspase cascade in the AT 2 receptor-induced apoptotic process are indicated.
Apoptosis induced by AT 2 receptor expression is not enhanced by Ang II nor inhibited by the AT 2 receptor antagonist Several lines of evidence suggest that the activation of programmed cell death may be a constitutive function of A seeming decrease in the apoptotic index at receptor densities <300 fmol/mg, by treatment with the AT 2 receptor antagonist PD123319, was not statistically signi®cant, indicating a lack of inhibition by the compound. The drug had no effect on apoptosis at receptor densities >300 fmol/mg. In another experiment, we varied the AT 2 receptor number from 10 to 720 fmol/mg protein, with and without [Sar 1 ]Ang II or PD123319, to measure the time of onset of apoptosis. The differences among the three conditions were small and not signi®cant. In the CHO cells, treatment with 0.1±10 mM [Sar 1 ]Ang II did not increase the percentage of apoptosis and also had no in¯uence on the apoptosis index (not shown).
To examine Ang II independence of various AT 2 receptor signals that contribute to apoptosis, we evaluated the potency of various pharmacological inhibitors on apoptosis with and without [Sar 1 ]Ang II treatment ( Figure 5 ). These experiments were carried out at two different levels of AT 2 receptor expression, 265 6 25 and 585 6 30 fmol/mg protein, as shown in Figure 5 . Combined treatment with [Sar 1 ]Ang II + PD98059 did not have a synergistic effect on apoptosis, as would be anticipated, at both levels of expression ( Figure 5 ). Furthermore, [Sar 1 ]Ang II treatment did not antagonize the inhibition of apoptosis by SB203580, and the caspase-3 inhibitor DEVD-cmk. The most unexpected observation from these studies is the lack of an apoptosis-activating effect by [Sar 1 ]Ang II. These ®ndings are comparable to the observations reported in earlier studies that indicate that Ang II does not induce the cascade of events that are hallmarks of receptor regulation by agonists. For instance, Pucell et al. (1991) and Hein et al. (1997) reported that Ang II does not stimulate endocytosis of the AT 2 receptor, implying that signals responsible for endocytosis are not generated. Similarly, AT 2 receptor±G i immune complex is insensitive to dissociation by GTPgS, unlike what would be expected (Zhang and Pratt, 1996) .
Blockade of AT 2 receptor-induced apoptosis by SB203580 suggests that members of the p38 MAPK family are recruited for mediating this process ( Figure 5 ). Accumulation of phospho-p38 MAPK in AT 2 -transfected cells is blocked by SB203580 but not affected by the agonist [Sar 1 ]Ang II and the antagonist PD123319 (Figure 6 ). This observation indicates that the p38 MAPK activation is linked to the level of expression of AT 2 receptor protein and not to activation of the AT 2 receptor by the ligand. The SB series inhibitors are proposed to be speci®c inhibitors of a and b isoforms of p38 MAPK. In some cell types (such as Jurkat lymphoma and HeLa cells), p38b is involved in attenuation of apoptosis and p38a in augmentation of apoptosis (Wang et al., 1998) . Assuming a similar mode of action in AT 2 receptor-transfected A7r5 and CHO cells, inhibition of p38a may shift the balance in favor of anti-apoptotic effects. Ectopic expression of p38 MAPK is known to induce cell death in PC12 cells (Wang et al., 1998) . Activated p38 MAPK is capable of phosphorylating the activating transcription factor-2 (Eliopoulos et al., 1999), which disregulates the cell cycle progression (Xia et al., 1995; Lavoie et al., 1996) .
AT 2 receptor expression-linked apoptosis is partially blocked by caspase-3 inhibitor but the inhibition is not altered by ligands of the AT 2 receptor ( Figure 5 ). However, [Sar 1 ]Ang II caused a signi®cant increase in caspase-3-like activity in both WT and N127G mutant receptor-transfected cells (Figure 7 ). This fraction of caspase-3-like activity could be suppressed by PD123319 + [Sar 1 ]Ang II treatment in both instances. Since PD123319 alone could not suppress caspase-3 activation by the WT AT 2 receptor and [Sar 1 ]Ang II treatment did not enable the N127G mutant to activate apoptosis, these observations together suggest that [Sar 1 ]Ang II-induced caspase-3-like activity is not only not suf®cient for inducing apoptosis in the N127G mutant but may also not be critical for apoptosis through the WT receptor. In contrast, caspase-3 activation by overexpression of the WT receptor is critical for apoptosis. The activation of caspase-3 is thought to be important for speci®c cleavage of the cell cycle regulatory proteins p21 waf1 and p27 kip1 in apoptotic cells (Levkau et al., 1998; Wang et al., 1998) .
Induction of apoptosis by the AT2 receptor through constitutive signal transduction In several cell culture models, recent studies have demonstrated that Ang II is capable of inducing antigrowth and apoptosis effects via the AT 2 receptors, which are not overexpressed. This anti-growth signaling is mediated by down-regulation of p42/p44 MAPK and apoptosis is considered to be an extreme form of antigrowth signaling. While apoptosis in coronary endothelial cells is proposed to be Ang II/AT 2 receptor mediated (Stoll et al., 1995) , in human umbilical endothelial cells it has been shown that the process is Ang II dependent but is not exclusively mediated by the AT 2 receptor, and depends on complex interplay between AT 1 and AT 2 receptors (Dimmler et al., 1997) . In cardiomyocytes, an entirely distinct mechanism for Ang II-induced apoptosis via the AT 1 receptor has been described (Kajstura et al., 1997) . Thus, Ang II-induced apoptosis in different cell types presents a complex picture.
Overexpression of AT 2 receptor generates signals that are distinct and may be important in vivo. In ovarian atretic follicles, granulosa cells that express high levels of AT 2 receptor also exhibit marked apoptosis mediating follicular atresia. Up-regulation of AT 2 receptor at sites of vascular injury, myocardial infarction, healing skin wound and remodeling uterine endometrium suggests that AT 2 receptor plays an important role in the pathophysiology of these remodeling processes. High levels of AT 2 receptor are expressed in adrenal medulla in the adult mammals where the role of AT 2 -induced apoptosis is not clear. High levels of AT 2 receptor expression are essential in the developing fetus where its primary role is to regulate apoptosis in ontogenic tissue. However, existing evidence is insuf®cient to conclude that Ang II stimulation of AT 2 receptor is a prerequisite for in vivo apoptosis in the remodeling process. Although the sequence of molecular events underlying the induction of AT 2 receptor overexpression in vivo is different from the experimental system here, our experiments suggest that the overexpressed AT 2 receptor was the source of the death signal that could be turned off only by mutation of the receptor and pharmacological interception of the signal¯ow (i.e. p38 MAPK inhibition, caspase-3 inhibition).
To reconcile the observations presented here with those reported earlier, we propose the model depicted in Figure 8 . We propose that overexpressed AT 2 receptors enhance a low tone signal that promotes the cells to enter programmed cell death. The activities of p38 MAPK and caspase-3 are integral components of this signal. A unique conformation of the WT receptor that is not signi®cantly affected by the binding of Ang II and PD123319 is essential. The apoptosis observed upon overexpression of the AT 2 receptor is merely a result of the increase in number of receptors, not the proportion of active and inactive receptor states, which is normally regulated by agonists and inverse agonists (Gether and Kobilka, 1998; Karnik, 2000) . Our model assumes that the receptor exists in a ®nite number of states, each of which could play a distinct role in the growth control of cells. It has recently been proposed that multiple-state models are better suited to the accurate depiction of the behavior of 7TM receptors (Chidiac, 1995) .
Although the results presented (Figure 4 ) suggest that the pro-apoptotic activity is a property of the entire population of AT 2 receptors, these experiments do not rule out the possibility that receptors attain a`different active state' conformation that uniquely triggers this process. Then why does Ang II not affect the apoptosis linked to this state by altering the equilibrium between various states? The observation needs further study, but the unique binding pro®le of Ang II analogs, which suggests that Ang II may function more like a neutral ligand, is an important consideration (Miura and Karnik, 1999) . In other receptors, neutral ligands do not disturb the equilibrium between different functional states of the receptor and may exhibit relatively uncommon zero ef®cacy. The behavior of PD123319 suggests that it functions as a competitive antagonist, not an inverse agonist (Gether and Kobilka, 1998) . Therefore, it is evident that modulation of the AT 2 receptor level plays the key role in vivo to switch the cells to apoptosis. Regulation by overexpression of signaling molecules is a relatively common paradigm, but the observation that additional hormone-independent signals lead to a distinctly different biological outcome represents a unique mode of regulation. Whether this type of regulation is unique to the AT 2 receptor or generally important in ontogenesis and remodeling is an unexplored question. The discovery of orphan G-protein coupled receptors (GPCRs) that are developmentally modulated might indicate that hormone-independent regulation by GPCRs may be more general than currently appreciated.
Regulation by increased tone of a ligand-independent signal through the overexpression of the receptor is not a well understood process and is irreconcilable with the prevailing concept of a two-state model for activation of a 7TM receptor: hormone binding (Ang II) activates the intracellular response and antagonist (PD123319) binding is able to block the signal. This type of signaling by the AT 2 receptor has been reported to induce an`anti-growth state' in many cell types and apoptosis (Pucell et al., 1991; Nakajima et al., 1995; Stoll et al., 1995; Yamada et al., 1996; Dimmeler et al., 1997; Matsubara, 1998; Horiuchi et al., 1999; Nishimura et al., 1999) . These studies also suggest that a mechanism that is not directly explained by the two-state model governs induction of apoptosis by the AT 2 receptor. Some of these questions have been alluded to above. Our experiments do not exclude agonistdependent signaling by the AT 2 receptor. Ang II-mediated inhibition of the p42/p44 MAPK by the AT 2 receptor is consistent with this model but raises several unanswered questions. For example, we do not yet know the key differences between anti-growth and the apoptotic signal transduction process. We suspect that coupling to speci®c members of the MAPK superfamily may be critical for Novel signaling by 7TM receptor different modes of AT 2 receptor function. We hope that experiments and the model described here will open a new window into the AT 2 receptor-coupled apoptotic process and facilitate additional studies into these questions. In summary, high-level expression of the AT 2 receptor as part of the fetal genetic program has been broadly implicated in ontogenesis, remodeling of adult tissues, development and differentiation. Transfected AT 2 receptor activates p38 MAPK-mediated apoptotic signaling and activation of cell death-promoting proteases. On the basis of the results presented here, we propose that induction of apoptosis is an intrinsic property of the native AT 2 receptor, limited by a threshold number of molecules per cell. One of the functions of the AT 2 receptor is to ensure abrupt switching to the apoptosis program, and our study suggests that Ang II activation is not essential for this function. The ®ndings in this study have important implications for the predicted functions of AT 2 receptors in vivo. Inductive control of AT 2 receptor expression in vivo is likely to be a contributory factor to tissue remodeling. We predict that the constitutive pro-apoptotic activity of the AT 2 receptor is the reason why AT 2 receptor expression is placed under inducible control. The observations presented here suggest that in vivo apoptosis induced by re-expression of the AT 2 receptor is likely to be a regulatory mechanism that is independent of the renin± angiotensin system.
Materials and methods

Materials
The following antibodies and reagents were generously provided as indicated or purchased: AT 2 receptor-selective non-peptide antagonist PD123319 (Research Biochemical International), a speci®c inhibitor of the MEK kinase, PD98059, 2-(2¢-amino-3¢-methoxyphenyl)oxanaphthalen-4-one (Biomol); the p38 MAP kinase inhibitor SB203580, 4-(4-uorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)1H-imidazole (Upstate Bio); the caspase-3 inhibitor, Ac-DEVD-chloro methyl ketone (Calbiochem); anti-phospho p38 MAPK antibody #9211S and anti-p38 MAPK antibody #9102 (New England Biolabs). 125 I-[Sar 1 ,Ile 8 ]Ang II was purchased from Dr Robert Speth, Washington State University.
Cell cultures and treatments
The mouse ®broblast line, R3T3 cells (Dudley et al., 1991) , CHO-K1 cells (ATCC CCL-61) (Kao and Puck, 1968) and the embryonic rat thoracic aorta-derived VSMC line, A7r5 cells (ATCC CRL-1444) (Kimes and Brandt, 1976) were cultured using penicillin-and streptomycinsupplemented Dulbecco's modi®ed Eagle's essential medium (DMEM) (Gibco-BRL) with 10% bovine calf serum (HyClone) in 5% CO 2 at 37°C. Apoptosis was measured in cells maintained for 48 h in DMEM containing 0.2% fetal calf serum. Cell viability was >95% by trypan blue exclusion analysis in control experiments. The level of AT 2 receptor stimulation was measured in the presence of 0.1 mM [Sar 1 ]Ang II (K d = 0.3 nM), and inhibition in the presence of 10 mM AT 2 selective non-peptide antagonist PD123319 (K d = 5 nM). [Sar 1 ]Ang II was added every 12 h to compensate for potential degradation. Inhibition experiments were performed in the presence of the p42/p44 MAPKspeci®c inhibitor PD98059 (30 mM), the p38 MAPK-speci®c inhibitor SB203580 (10 mM) and the caspase-3 inhibitor (1 mM) for 48 h after transfection.
VSMCs and CHO cell transfection
The expression vector pcDNA3-AT 2 R contains rat AT 2 receptor cDNA (Invitrogen). In mock transfection control samples, the pcDNA3 empty vector (without the AT 2 receptor cDNA insert) was used. To vary the expression levels of the AT 2 receptor without compromising the transfection ef®ciency (>80%), the plasmid DNA concentration was maintained constant (12 mg/plate), but the ratio of pcDNA3:pcDNA-AT 2 R was varied (see legend to Figure 5 ). The pAT 2 R-EYFP expression vector was constructed by fusion of the coding sequence of EYFP (Clontech) to the 3¢ end of the AT 2 receptor coding sequence. Cells were transfected using DOSPER [1,3-di-oleoyloxy-2-(6-carboxyspermyl)-propylamid] liposomal reagent according to the manufacturer's instructions (Boehringer Mannheim). The ef®ciency of transfection in each experiment was estimated in parallel from transfection of 12 mg/plate p-EYFP. Cells were harvested and¯ow cytometric analysis was conducted by using FACS (Becton Dickinson).
Immunoblotting
For each time point or manipulation, protein extracts were prepared from a 100 mm plate. After the cells were washed, lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 0.2 mM sodium orthovanadate, 0.2 mM phenylmethylsulfonyl¯uoride, 0.5% NP-40) was added, scraped, transferred to a microcentrifuge tube, and boiled for 5 min. The viscosity of the sample was reduced using a Microsonâ ultrasonic cell disrupter, followed by centrifugation for 5 min. Total protein content in the supernatant was determined by the bicinchoninic acid method (Pierce). An equal amount of protein (10±30 mg) per well was loaded onto 10% SDS±PAGE gels. Western blot analysis was performed with primary antibodies as speci®ed in each case. Horseradish peroxidase-conjugated secondary antibody and the enhanced chemiluminescent substrate system (Amersham) were used as a detection system. The signal was independently quanti®ed by a digital image analysis system (Eastman Kodak Company, Rochester, NY).
Analysis of apoptosis R3T3 cells. Apoptotic cells were determined by the in situ Cell Death Detection Kit as per the manufacturer's protocol (Boehringer Mannheim). Brie¯y, cells were ®xed in 4% paraformaldehyde and terminal deoxynucleotide transferase-mediated deoxyuridine 5¢-triphosphate nicked end labeling (TUNEL) reaction mix was added. Anti-BrdU antibody Fab fragment conjugated with horseradish peroxidase and the metal-enhanced substrate 3,3¢-diaminobenzidine were added next. Cells were analyzed by light microscopy.
VSMCs and CHO cells. Apoptotic cells were determined by TUNEL¯ow cytometry using the APO-BRDU TM kit (Phoenix Flow Systems, Inc.). Brie¯y, cells were ®xed with 1% paraformaldehyde and washed and then labeled with Br-dUTP using the terminal deoxynucleotide transferase enzyme. Cells were stained with the¯uorescein±PRB-1 antibody. Propidium iodide/RNase solution was added to remove RNA and label nuclear DNA. Cells were analyzed by¯ow cytomety using Vantage [Becton Dickinson, San Jose, CA (a gift from the Keck foundation)]. The same samples were imaged using a Leica TCS-SP laser scanning confocal microscope. For imaging, the cells were plated on lysine-coated microscope slides and after transfection the cells were ®xed with 1% paraformaldehyde at 4°C for 15 min. The slides were then stained with DAPI for detection of chromatin condensation. The cells were imaged using a Leika DMIRB digital¯uorescent microscope.
Caspase-3-like activity assay Caspase-3-like protease activity was determined by colorimetric assay using the CaspACE TM assay system (Promega) according to the manufacturer's instructions. Transfected and control cells (10 6 ) were lysed in the lysis buffer by freezing and thawing, followed by centrifugation (15 000 g for 20 min at 4°C). Caspase-3-like activity was measured in supernatants by following the proteolytic cleavage of the colorimetric substrate Ac-DEVD-pNA. DEVD-pNA was used as standard in assay buffer (l max 405 nm).
Receptor binding assay
The ligand binding experiments were carried out as described earlier (Noda et al., 1996; Miura and Karnik, 1999 
Statistical analysis
The results are expressed as the mean 6 SEM of three or more independent determinations. Signi®cant differences in measured values were evaluated with an analysis of variance with Bonferroni's test and unpaired Student's t-test. Pearson product moment correlation coef®-cients were calculated. Statistical signi®cance was set at p <0.05.
